The patents provide protection in a market where approximately 18,000 new cases of acute myelogenous leukemia (AML) are diagnosed each year and the trend in overall incidence of AML has been gradually increasing.
Based on this development, Critical Outcome Technologies (COTI) will carry out a targeted marketing strategy to identify and select a licensing partner amongst European pharmaceutical organizations. The expected granting of the corresponding patents in North America is said to further strengthen the company’s patent portfolio and provide additional impetus to licensing negotiations.
Wayne Danter, president and chief scientific officer of COTI, said: “The granting of these patents by the experienced examiners of the European Patent Office represents a further validation of our proprietary technology, Chemsas. These patents are valuable assets that can be licensed to partners eager to develop novel therapeutics for the treatment of this disease.”